4/A: Brainstorm Cell Therapeutics CEO Corrects Transaction Code in Form 4 Amendment

Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, files an amendment to a previous Form 4 to correct a transaction code related to a purchase of common stock.

Summary

• Chaim Lebovits, the President and CEO of Brainstorm Cell Therapeutics Inc., filed an amended Form 4 with the SEC on July 31, 2024.
• This amendment corrects an error in the original Form 4 filed on June 3, 2024, which incorrectly listed the transaction code as 'A'.
• The corrected form shows that on May 28, 2024, Lebovits purchased 15,000 shares of Brainstorm Cell Therapeutics' common stock at a weighted average price of $0.5183 per share.
• The purchase was made directly, and following the transaction, Lebovits directly owns 1,164,865 shares.
• Lebovits may also be deemed the beneficial owner of 2,000,847 indirectly owned shares.
• These indirectly owned shares include 1,933,794 shares held by ACCBT Corp. and 67,053 shares held by ACC International Holdings Ltd.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting an administrative error. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's securities, ensuring transparency and compliance with SEC regulations.

Key Dates

Keywords

Form 4, Amendment, Beneficial Ownership, Chaim Lebovits, Brainstorm Cell Therapeutics, BCLI, SEC Filing, Common Stock, Transaction Code